Vaxart's teslexivir misses in Phase II for anogenital warts

Vaxart Inc. (NASDAQ:VXRT) said twice-daily topical teslexivir (BTA074) 5% gel missed the primary endpoint of improving the complete clearance rate of baseline anogenital warts (condyloma) by week 16 vs. placebo in a Phase II trial in 218 patients (30.6% vs. 23.3%). The company, which announced the news in June, plans to conduct further analysis of the double-blind, international trial to determine next steps...